Anbio Biotechnology is a Germany-based company. The Company is engaged in the development of medical technology and the provision of in vitro diagnostics (IVD) products. Its products encompasses solutions for various applications, including over-the-counter (OTC) utilization, point-of-care (POCT) settings, and laboratory applications. The Company's product detects biomarkers associated with medical domains. These domains encompasses infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. In addition, the Company's IVD products are in line with multiple sample collection matrices, including serum, plasma, whole blood, feces, urine, and saliva, for both healthcare providers and patients. Its primary research and development activities for all IVD products includes Biomarker Discovery and Validation, Assay Development, Validation - Clinical and Analytical and Platform Transfer.